N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.812 NOK 4.38% Market Closed
Market Cap: 918.2m NOK
Have any thoughts about
Nykode Therapeutics ASA?
Write Note

Nykode Therapeutics ASA
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nykode Therapeutics ASA
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
N
Nykode Therapeutics ASA
OSE:NYKD
Depreciation & Amortization
-$2.3m
CAGR 3-Years
-81%
CAGR 5-Years
-255%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Depreciation & Amortization
-kr38.6m
CAGR 3-Years
-5%
CAGR 5-Years
-9%
CAGR 10-Years
-11%
B
Bergenbio ASA
OSE:BGBIO
Depreciation & Amortization
-kr416k
CAGR 3-Years
29%
CAGR 5-Years
8%
CAGR 10-Years
N/A
L
Lytix Biopharma AS
OSE:LYTIX
Depreciation & Amortization
-kr962k
CAGR 3-Years
N/A
CAGR 5-Years
-149%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Depreciation & Amortization
-kr6m
CAGR 3-Years
-27%
CAGR 5-Years
-7%
CAGR 10-Years
-9%
T
Thor Medical ASA
OSE:TRMED
Depreciation & Amortization
-kr731k
CAGR 3-Years
61%
CAGR 5-Years
34%
CAGR 10-Years
-14%
No Stocks Found

Nykode Therapeutics ASA
Glance View

Market Cap
918.2m NOK
Industry
Biotechnology

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

NYKD Intrinsic Value
0.181 NOK
Overvaluation 94%
Intrinsic Value
Price
N

See Also

What is Nykode Therapeutics ASA's Depreciation & Amortization?
Depreciation & Amortization
-2.3m USD

Based on the financial report for Jun 30, 2024, Nykode Therapeutics ASA's Depreciation & Amortization amounts to -2.3m USD.

What is Nykode Therapeutics ASA's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-255%

Over the last year, the Depreciation & Amortization growth was -18%. The average annual Depreciation & Amortization growth rates for Nykode Therapeutics ASA have been -81% over the past three years , -255% over the past five years .

Back to Top